CAS 625853-74-9
:5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-5-hydroxy-thiazolidin-2,4-dion
- 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-5-hydroxy-
- 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-5-hydroxy-2,4-thiazolidinedione
- Pioglitazone EP IMpurity A
- Pioglitazone EP Impurity A (Pioglitazone 5-Hydroxy Metabolite)
- Pioglitazone impurities1586
- Pioglitazone Impurity A(EP)
- Pioglitazone Impurity A
- 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]Methyl]-5-hydroxy-
- 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-5-hydroxy-1,3-thiazolidine-2,4-dione
- 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-5-hydroxythiazolidine-2,4-dione
- Pioglitazone IMpurity A (5-Hydroxy Pioglitazone)
- Pioglitazone EP Impurity
- 5-Hydroxy Pioglitazone
- Pioglitazone Impurity 8(Pioglitazone EP Impurity A)
- Weitere Synonyme anzeigen
Pioglitazone EP Impurity A
CAS:Formel:C19H20N2O4SFarbe und Form:White To Off-White SolidMolekulargewicht:372.445-Hydroxy pioglitazone
CAS:Pioglitazone is a thiazolidinedione that is used to treat type 2 diabetes. It is an agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), which causes a decrease in insulin resistance and glucose production by the liver, leading to improved glycemic control. Pioglitazone has been shown to have a low potential for drug interactions mediated by cytochrome P450 enzymes. Pioglitazone also has a low potential for drug interactions with other PPARγ agonists because it does not inhibit the enzyme responsible for their metabolism and elimination from the body. Studies have been conducted using liquid chromatography and validated methods to measure levels of pioglitazone and its active metabolites in human plasma following oral administration. The pharmacokinetics of pioglitazone are linear, with an average bioavailability of about 10%. The flow rate of pioglitazone can be determined using mass spectrometry methods.
Formel:C19H20N2O4SReinheit:Min. 95%Molekulargewicht:372.44 g/mol


